MedTrace Logo

Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

NCT01147276 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-09-25

No results posted yet for this study

Summary

The study examines whether DPP-4 inhibition by vildagliptin affects the glucagon counterregulatory response to hypoglycemia in type 1 diabetes.

Conditions

Interventions

DRUG

Vildagliptin

Vildagliptin (50 mg BID) in four weeks

Sponsors & Collaborators

  • Lund University

    lead OTHER

Principal Investigators

  • Bo Ahrén, PhD MD · Lund University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-09-30
Completion
2011-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147276 on ClinicalTrials.gov